Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of November 2020, specifically reporting a transaction notification dated November 3, 2020. The filing serves as a disclosure of insider trading activity rather than a periodic financial report.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific securities transaction:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053
- Transaction Type: Purchase
- Volume: 4,380 ADSs
- Price: $34.229 per ADS
- Date: November 2, 2020
- Exchange: New York Stock Exchange (XNYS)
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing is a regulatory notification of a single purchase transaction by a Person Discharging Managerial Responsibilities (PDMR).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a standard transaction notification required under the Securities Exchange Act of 1934.
Investor Verification Points
- Verify the identity of the purchaser: Ms. D Conrad, SVP, Human Resources.
- Confirm the transaction date (November 2, 2020) and price ($34.229) against market data for GSK ADSs on that date.
- Note that this filing does not reflect the company's overall financial health or quarterly results.